Stockscreener 앱 받기
125.00
0.33%
0.41
시장 영업 전:
125.00
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Risk vs reward if holding onto Jazz Pharmaceuticals plc2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Is Jazz Pharmaceuticals plc stock entering bullish territoryShare Buyback & Daily Profit Focused Screening - Newser
Will Jazz Pharmaceuticals plc bounce back from current supportJuly 2025 Analyst Calls & Community Verified Swing Trade Signals - Newser
Pattern recognition hints at Jazz Pharmaceuticals plc upsideLayoff News & Scalable Portfolio Growth Methods - Newser
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Using data tools to time your Jazz Pharmaceuticals plc exitWeekly Gains Summary & Verified Entry Point Signals - Newser
What to do if you’re stuck in Jazz Pharmaceuticals plcWeekly Volume Report & AI Powered Market Entry Ideas - Newser
Analyzing recovery setups for Jazz Pharmaceuticals plc investorsChart Signals & Low Volatility Stock Suggestions - Newser
What technical models suggest about Jazz Pharmaceuticals plc’s comebackWeekly Trade Recap & High Accuracy Investment Entry Signals - Newser
Using data filters to optimize entry into Jazz Pharmaceuticals plcPortfolio Profit Report & Real-Time Buy Zone Alerts - Newser
Can Jazz Pharmaceuticals plc recover in the next quarterPortfolio Gains Report & Risk Controlled Daily Plans - Newser
Chart overlay techniques for tracking Jazz Pharmaceuticals plcForecast Cut & High Win Rate Trade Alerts - Newser
News impact scoring models applied to Jazz Pharmaceuticals plcGDP Growth & Stepwise Trade Execution Plans - Newser
US Narcolepsy Drugs Market Outlook and Company Analysis Report 2025-2033 Featuring Jazz Pharma, Liga - PharmiWeb.com
Can Jazz Pharmaceuticals plc grow without dilution2025 Top Gainers & Consistent Profit Trading Strategies - sundaytimes.kr
Has Jazz Pharmaceuticals plc formed a bullish divergenceNew Guidance & Breakout Confirmation Trade Signals - Newser
Developing predictive dashboards with Jazz Pharmaceuticals plc dataPortfolio Performance Report & Consistent Profit Focused Trading Strategies - Newser
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should Know2025 EndofYear Setup & Daily Growth Stock Investment Tips - Newser
Is Jazz Pharmaceuticals plc stock a smart retirement pick2025 Risk Factors & Real-Time Volume Surge Alerts - theviewers.co.kr
Combining machine learning predictions for Jazz Pharmaceuticals plcWall Street Watch & Growth-Oriented Investment Plans - Newser
BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217 - MSN
Jazz Pharmaceuticals to Present at 2025 Wells Fargo Healthcare Conference - AInvest
Jazz Pharmaceuticals (JAZZ): Valuation in Focus After Major Epilepsy Drug Deal and Leadership Change - simplywall.st
Jazz Pharmaceuticals to Participate in Wells Fargo Healthcare Conference - AInvest
Global Biopharma Leader Jazz Pharmaceuticals to Share Updates at Wells Fargo Healthcare Conference 2025 - Stock Titan
Will Breakout in Jazz Pharmaceuticals plc Sustain Through Next WeekQuarterly Portfolio Review & Technical Pattern Based Buy Signals - 더경남뉴스
Jazz gains rights to Saniona’s SAN-2355 - BioWorld MedTech
Earnings call transcript: Jazz Pharmaceuticals’ Q2 2025 earnings miss expectations, stock drops - Investing.com
AI Indicators Detect Buy Opportunity in Jazz Pharmaceuticals plcJuly 2025 Volume & Fast Gain Stock Trading Tips - 더경남뉴스
What MACD signals say about Jazz Pharmaceuticals plcVolume Spike & Comprehensive Market Scan Insights - Newser
Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal - insights.citeline.com
First-Ever FDA-Approved Treatment: Jazz's Modeyso Breakthrough for Aggressive Brain Tumor Patients - Stock Titan
Jazz pharmaceuticals acquires rights to Saniona’s epilepsy drug candidate By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement - Contract Pharma
Why Jazz Pharmaceuticals (JAZZ) Is Up 5.2% After Modeyso Receives FDA Approval for Rare Brain Cancer - simplywall.st
Jazz pharmaceuticals acquires rights to Saniona’s epilepsy drug candidate - Investing.com
Jazz Pharmaceuticals licenses epilepsy drug from Saniona for $42.5M - StreetInsider
$1 Billion Deal: Jazz Pharma Secures Rights to Revolutionary Epilepsy Drug SAN2355 from Saniona - Stock Titan
Jazz Pharmaceuticals price target lowered to $165 from $166 at Morgan Stanley - MSN
Price action breakdown for Jazz Pharmaceuticals plcDollar Strength & Fast Moving Stock Trade Plans - Newser
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
Using flow based indicators on Jazz Pharmaceuticals plcMarket Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Jazz Pharmaceuticals plc Shows Early Signs of Technical Strength2025 Pullback Review & Expert Verified Movement Alerts - kangso.co.kr
Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca - MSN
AI Trend Models Suggest Bounce for Jazz Pharmaceuticals plcPortfolio Gains Report & Technical Pattern Based Buy Signals - 선데이타임즈
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks - Yahoo Finance
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt - 富途牛牛
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Bollinger Band Squeeze Points to Volatility in Jazz Pharmaceuticals plc2025 Historical Comparison & Weekly Hot Stock Watchlists - classian.co.kr
Should you hold or exit Jazz Pharmaceuticals plc nowTrade Volume Report & Daily Technical Stock Forecast Reports - Newser
Jazz Pharmaceuticals plc Approaches Psychological Resistance LevelEarnings Miss & Trade Opportunity Analysis Reports - sisa-n.com
0.95%
0.90%
자본화:
|
볼륨(24시간):